Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

被引：12
|
作者：
Lim, Emerson A.
Schweizer, Michael Thomas
Chi, Kim N.
Aggarwal, Rahul Raj
Agarwal, Neeraj
Gulley, James L.
Attiyeh, Edward F.
Greger, James
Wu, Shujian
Jaiprasart, Pharavee
Loffredo, John
Bandyopadhyay, Nibedita
Xie, Hong
Hansen, Aaron Richard
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Univ British Columbia, BC Canc Agcy, Vancouver, BC, Canada
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[6] NCI, NIH, Bethesda, MD 20892 USA
[7] Janssen Res & Dev, Spring House, PA USA
[8] Janssen Res & Dev, Horsham, PA USA
[9] Janssen Res & Dev, Raritan, NJ USA
[10] Janssen Res & Dev LLC, Spring House, PA USA
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
279
引用
收藏
页数：3
相关论文
共 28 条
  • [1] Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
    Lim, Emerson A.
    Schweizer, Michael T.
    Chi, Kim N.
    Aggarwal, Rahul
    Agarwal, Neeraj
    Gulley, James
    Attiyeh, Edward
    Greger, James
    Wu, Shujian
    Jaiprasart, Pharavee
    Loffredo, John
    Bandyopadhyay, Nibedita
    Xie, Hong
    Hansen, Aaron R.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 366 - 375
  • [2] Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
    Geva, R.
    Vieito Villar, M.
    Ramon, J.
    Perets, R.
    Pedregal, M.
    Corral de la Fuente, E.
    Doger de Speville, B.
    Calvo, E.
    Bardina, J.
    Garralda, E.
    Brown, R. J.
    Gregor, J.
    Wu, S.
    Steinbach, D.
    Tsun-wen, S.
    Cao, Y.
    Lauring, J.
    Moreno Garcia, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S634
  • [3] Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
    Reed-Perino, Darien E.
    Lai, Michael
    Yu, Evan Y.
    Schweizer, Michael T.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (05)
  • [4] A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
    Stein, M. N.
    Graham, L. S.
    Baldini, C.
    Vinceneux, A.
    Kessler, E.
    Runcie, K.
    Wei, A. Z.
    Papadopoulos, K. P.
    Bernard-Tessier, A.
    Laurent, M.
    Jaiprasart, P.
    Thaper, D.
    Shen, F.
    Cartee, L.
    Attiyeh, E.
    Villalobos, V. M.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1000 - S1000
  • [5] JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study
    Calvo, E.
    Doger de Speville, B.
    Carles Galceran, J.
    Peer, A.
    Sarid, D. L.
    Eigl, B. J.
    Avadhani, A.
    Yao, D.
    Lin, V.
    Wu, S.
    Jaiprasart, P.
    Loffredo, J.
    Tamegnon, M.
    Xie, H.
    Hansen, A. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1166 - S1166
  • [6] Anti-PSMA X Anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-resistant Prostate Cancer Models
    Sewell, T.
    Hernandez-Hoyos, G.
    Chenault, R. A.
    Wiens, J.
    Kumer, J.
    Natarajan, S.
    McMahan, C. J.
    Algate, P. A.
    Blankenship, J. W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 98 - 98
  • [7] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer
    Kulkarni, Harshad
    Weineisen, M.
    Mueller, Dirk
    Schuchardt, Christiane
    Schottelius, Margret
    Wester, Hans
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [9] LUTETIUM-177 LABELLED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND LIGANDS FOR THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC): A SYSTEMATIC REVIEW AND META-ANALYSIS
    Calopedos, Ross
    Chalasani, Venu
    Asher, Rebecca
    Emmett, Louise
    Woo, Henry H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 41 - 42
  • [10] Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Markowski, Mark Christopher
    Kilari, Deepak
    Eisenberger, Mario A.
    Mckay, Rana R.
    Dreicer, Robert
    Trikha, Mohit
    Heath, Elisabeth I.
    Li, Jing
    Garzone, Pamela D.
    Young, Travis S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
123